Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Clopipazan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 7/20 | 0.50 |
| ▸ | DRD4 known ✓ | P21917 | 6/20 | 0.50 |
| ▸ | HTR1A known ✓ | P08908 | 5/20 | 0.50 |
| ▸ | ADRA2A known ✓ | P08913 | 5/20 | 0.50 |
| ▸ | DRD1 known ✓ | P21728 | 5/20 | 0.50 |
| ▸ | SLC6A2 known ✓ | P23975 | 5/20 | 0.50 |
| ▸ | SLC6A4 known ✓ | P31645 | 5/20 | 0.50 |
| ▸ | ADRA1A known ✓ | P35348 | 5/20 | 0.50 |
| ▸ | DRD3 known ✓ | P35462 | 5/20 | 0.50 |
| ▸ | SLC6A3 known ✓ | Q01959 | 5/20 | 0.50 |
| ▸ | CHRM1 known ✓ | P11229 | 4/20 | 0.50 |
| ▸ | ADRA2B known ✓ | P18089 | 4/20 | 0.50 |
| ▸ | ADRA2C known ✓ | P18825 | 4/20 | 0.50 |
| ▸ | HTR2A known ✓ | P28223 | 4/20 | 0.50 |
| ▸ | HTR2C known ✓ | P28335 | 4/20 | 0.50 |
| ▸ | HTR3A known ✓ | P46098 | 3/20 | 0.50 |
| ▸ | ADRB2 known ✓ | P07550 | 2/20 | 0.50 |
| ▸ | DRD5 known ✓ | P21918 | 2/20 | 0.50 |
| ▸ | ADRA1D known ✓ | P25100 | 3/20 | 0.42 |
| ▸ | TACR1 known ✓ | P25103 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clopipazan SCHEMBL1816896 | 0.92 | SETD7 (0.76) | SETD7DRD2DRD4HRH1CHRM2 | |
| SCHEMBL11574882 | 0.88 | SETD7 (0.48) | SETD7DRD2DRD4HRH1CHRM2 | |
| SCHEMBL11574590 | 0.88 | HRH4 (0.50) | SETD7DRD2DRD4HRH1CHRM2 | |
| Clopipazan SCHEMBL11573662 | 0.87 | SETD7 (0.61) | SETD7DRD2DRD4HRH1CHRM2 | |
| Clopipazan SCHEMBL11573664 | 0.87 | SETD7 (0.61) | SETD7DRD2DRD4HRH1CHRM2 | |
| SCHEMBL11576549 | 0.85 | SETD7 (0.49) | SETD7DRD2DRD4HRH1CHRM2 | |
| SCHEMBL11576546 | 0.85 | DRD2 (0.46) | SETD7DRD2DRD4HRH1CHRM2 | |
| SCHEMBL11574884 | 0.81 | SETD7 (0.47) | SETD7DRD2DRD4HRH1CHRM2 | |
| SCHEMBL5905710 | 0.80 | SETD7 (1.00) | SETD7DRD2DRD4HRH1CHRM2 | |
| SCHEMBL11600718 | 0.79 | SETD7 (0.50) | SETD7DRD2DRD4HRH1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1044023-B1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | LUITPOLD PHARM INC (US) | 2005-05-25 | — | — | EP | claimed |
| US-6197764-B1 | COMPLEX WITH FATTY ACID; THERAPY FOR PSYCHOLOGICAL DISORDERS | PROTARGA, INC. | 2001-03-06 | — | — | US | claimed |
| EP-1044023-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | Protarga Inc. (US) | 2000-10-18 | — | — | EP | claimed |
| US-5955459-A | Fatty acid-antipsychotic compositions and uses thereof | NEUROMEDICA, INC. (US) | 1999-09-21 | — | — | US | claimed |
| WO-1999026661-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | PROTARGA INC. (US) | 1999-06-03 | — | — | WO | claimed |
| EP-3749325-B1 | DREADD ACTUATORS | US HEALTH (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250339367-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| WO-1999026661-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | PROTARGA INC. (US) | 1999-06-03 | — | — | WO | disclosed |
| EP-0909183-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | Neuromedica, Inc. (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| US-5780051-A | Methods and articles of manufacture for nicotine cessation and monitoring nicotine use | DYNAGEN, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | DRD2 584/4885DRD4 781/4885HTR1A 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.